Answers are grounded in this paper and cite their sources.
The role of cytoreductive surgery for epithelioid pleural mesothelioma within a multimodal treatment approach remains controversial. Carefully selected patients benefit from cytoreductive surgery and adjuvant chemotherapy, but there is no established biomarker to predict tumor recurrence or progression during the course of the disease. The aim of this study was to identify potential biomarkers to predict therapeutic response in terms of progression-free survival.
No takes yet. Share an insight, caveat, or question.
Klotz et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: